Skip to main content

There’s Power Lurking in This Pharma ETF

Blue-chip pharmaceuticals stocks are turning solid showings this year, but the group is lagging the broader market, indicating that some of the coronavirus vaccine blush is wearing off the group. However, some market observers see avenues for big pharma equity upside in 2022 and, if accurate, that...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.